Background: Androgenetic alopecia (AGA), which affects more than 70% of adult males and 50% of adult females, is the most common type of hair loss and is a genetically defined progressive process that gradually converts terminal hair into vellus hair. AGA is a benign condition that can significantly affect a person's psychological state and is influenced by both hormonal and hereditary factors. Aims and Objectives: This study was planned to understand the effect of finasteride on the quality of life of an androgenetic alopecia (AGA) patient. Methods and materials:This observational, prospective, open-label study was conducted in the outpatient department of dermatology in collaboration with the Pharmacology department, included a total of 80 male patients with AGA Grade I–VII of the Hamilton–Norwood classification who were between the ages of 18 and 60 years. Results: The mean age of 30.5 ± 6.41 years; the average duration of hair loss was 24.5 months; and the maximum number of cases were in grade II, which was 27 (33.75%). About 86.25% patients showed improvement in hair growth; loss of hair in 6.25% was seen; in grade-wise analysis, maximum improvement was seen in grade II and grade III patients. Average DLQI scores before the treatment were 9.16 ±1.92, which decreased to 5.27±2.80 after the treatment. This difference was statistically significant (p <0.005). A higher DLQI means a poorer quality of life. Conclusion: This study indicates that treatment with finasteride improves hair growth considerably, which improves the quality of life in male patients with androgenous phalacrosis. Finasteride showed significant improvement in the progression of AGA in males. Keywords: Androgenic Alopecia, Finasteride, Hair Loss, Quality Of Life (QoL)